Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNovacyt Regulatory News (NCYT)

Share Price Information for Novacyt (NCYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 64.00
Bid: 63.40
Ask: 66.00
Change: -1.50 (-2.27%)
Spread: 2.60 (4.101%)
Open: 64.00
High: 64.00
Low: 64.00
Prev. Close: 66.20
NCYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Yourgene Health plc

8 Sep 2023 12:00

RNS Number : 8668L
Stifel Nicolaus Europe Limited
08 September 2023
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Stifel Nicolaus Europe Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Yourgene Health plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Yourgene Health plc

(d) Date dealing undertaken:

07 September 2023

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary

Buy

587,379

0.5126 GBX

0.5126 GBX

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

Date of disclosure:

08 September 2023

Contact name:

Jordan Gaskell

Telephone number:

0207 710 7482

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEREAPNPEFLDEEA
Date   Source Headline
18th Mar 20226:00 pmRNSDirector/PCA Dealing
15th Mar 20222:30 pmRNSDirector/PDMR Shareholding
11th Mar 20228:00 amRNSHoldings in Company
1st Mar 20221:00 pmRNSLiquidity Agreement Update and Total Voting Rights
18th Feb 20224:05 pmRNSHoldings in Company
17th Feb 20227:00 amRNSApproval of COVID-19 test under CTDA legislation
15th Feb 20224:00 pmRNSHoldings in Company
4th Feb 20227:00 amRNSLong Term Incentive Plan
1st Feb 20222:30 pmRNSLiquidity Agreement and Total Voting Rights
25th Jan 20227:00 amRNSStrategy and Full Year 2021 Trading Update
4th Jan 20224:30 pmRNSLiquidity Agreement and Total Voting Rights
1st Dec 20212:30 pmRNSTotal Voting Rights
26th Nov 20217:00 amRNSApproval of COVID-19 test under CTDA legislation
2nd Nov 20217:00 amRNSValidation of COVID-19 tests in the UK under CTDA
1st Nov 20215:30 pmRNSLiquidity Agreement and Total Voting Rights
19th Oct 20214:15 pmRNSResults of annual general meeting
1st Oct 20212:30 pmRNSTotal Voting Rights
30th Sep 20217:00 amRNSR&D update
29th Sep 20215:00 pmRNSNotice of AGM
29th Sep 20217:00 amRNSNotice of rescheduled AGM
27th Sep 20217:00 amRNSHalf year 2021 results
16th Sep 20217:00 amRNSProposed accounting treatment of DHSC dispute
13th Sep 20217:00 amRNSAGM voting
1st Sep 202111:30 amRNSLiquidity Agreement and Total Voting Rights
20th Aug 20217:00 amRNSNotice of AGM
18th Aug 20217:00 amRNSHalf Year Update
5th Aug 20217:00 amRNSNotice of investor meeting
2nd Aug 20211:30 pmRNSTotal Voting Rights
29th Jul 20217:00 amRNSDavid Allmond to be CEO, Graham Mullis to retire
6th Jul 20212:40 pmRNSDirector/PDMR Shareholding
1st Jul 20212:30 pmRNSLiquidity Agreement and Total Voting Rights
29th Jun 20217:00 amRNSPublication of Annual Report
29th Jun 20217:00 amRNSExpansion of PathFlow COVID-19 LFT portfolio
22nd Jun 20217:00 amRNSFull year 2020 results and update on strategy
18th Jun 20217:00 amRNSUpdate on Notice of 2020 Full Year Results
3rd Jun 20217:00 amRNSLaunch of two new PCR COVID-19 assays
1st Jun 20212:00 pmRNSLiquidity Agreement and Total Voting Rights
26th May 20217:00 amRNSLaunch of VersaLab Portable
21st May 20217:00 amRNSDHSC Dispute Update
17th May 20217:00 amRNSInclusion of SNPsig in the NHS England Framework
4th May 20211:00 pmRNSTotal Voting Rights
4th May 20217:00 amRNSNovacyt donates 1 million COVID-19 tests to UNICEF
23rd Apr 20217:00 amRNSR&D and UK operational update
22nd Apr 20217:00 amRNSNotice of Results
9th Apr 202112:30 pmRNSTrading Update
1st Apr 20211:40 pmRNSTotal Voting Rights
24th Mar 20217:00 amRNSLaunch of VariPLEX CE-Mark test
17th Mar 20217:11 amRNSLaunch of mobile processing laboratories
15th Mar 20214:45 pmRNSHoldings in Company
15th Mar 202111:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.